Aytu BioPharma (LTS:0A8M) Total Liabilities: $76.55 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A8M Aytu BioPharma Inc LTS:0A8M
40 GF Score
Price $2.20
GF Value $0.87
! 3 Warning Signs
View Full Analysis

What is Aytu BioPharma Total Liabilities?

Aytu BioPharma LTS:0A8M 40 Total Liabilities is $76.55 Mil as of Mar. 2026. GuruFocus rates LTS:0A8M with a GF Score™ of 40/100 and a GF Value™ of $0.87. The stock has 3 warning signs investors should review.

Aytu BioPharma's Total Liabilities for the quarter that ended in Mar. 2026 was $76.55 Mil.

Aytu BioPharma's quarterly Total Liabilities increased from Sep. 2025 ($101.82 Mil) to Dec. 2025 ($107.80 Mil) but then declined from Dec. 2025 ($107.80 Mil) to Mar. 2026 ($76.55 Mil).

Aytu BioPharma's annual Total Liabilities declined from Jun. 2023 ($97.11 Mil) to Jun. 2024 ($90.38 Mil) but then increased from Jun. 2024 ($90.38 Mil) to Jun. 2025 ($105.21 Mil).

Aytu BioPharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aytu BioPharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aytu BioPharma Total Liabilities Chart

Aytu BioPharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.10 93.32 97.11 90.38 105.21

Aytu BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.30 105.21 101.82 107.80 76.55
LTS:0A8M
40GF Score
Aytu BioPharma Inc LTS:0A8M
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aytu BioPharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aytu BioPharma's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=63.064+(10.895+31.252
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=105.21

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=124.177-18.966
=105.21

Aytu BioPharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=59.972+(9.549+7.025
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=76.55

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=111.689-35.143
=76.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $76.55 Mil mean?
Aytu BioPharma (LTS:0A8M) has a Total Liabilities of $76.55 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aytu BioPharma and its competitors.
Is Aytu BioPharma's Total Liabilities too high?
Aytu BioPharma's current Total Liabilities is $76.55 Mil. Overall, Aytu BioPharma has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Total Liabilities compare to TXMD and CPHI?
Aytu BioPharma's Total Liabilities of $76.55 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aytu BioPharma and its competitors. Aytu BioPharma's current Total Liabilities is $76.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Aytu BioPharma (LTS:0A8M) has a current Total Liabilities of $76.55 Mil. The stock's GF Value™ is $0.87, compared to a current price of $2.20 — trading 152.9% above its estimated fair value. The current Total Liabilities is $76.55 Mil. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Aytu BioPharma (LTS:0A8M), the current Total Liabilities is $76.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aytu BioPharma (LTS:0A8M) Overvalued in 2026?

Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued. The current stock price of $2.20 is trading 152.9% above its estimated GF Value™ of $0.87.

Key valuation signals for LTS:0A8M:

  • Total Liabilities: $76.55 Mil
  • GF Value™: $0.87 vs. price of $2.20 (152.9% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the LTS:0A8M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aytu BioPharma Business Description

Other Exchanges AYTU:USA
Address 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score

Get the complete analysis for LTS:0A8M

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.20
Price
$0.87
GF Value